Market Perspectives on the (In Vitro) Diagnostics Industry
|
|
- Harold Potter
- 6 years ago
- Views:
Transcription
1 Market Perspectives on the (In Vitro) Diagnostics Industry Ranald Sutherland For MTIC Wednesday, January 20,
2 Topics Overall market size and segmentation Major trends and drivers Consolidation of Suppliers Growth Driver; POC Growth Driver; Molecular Diagnostics Growth Driver; Companion Diagnostics Investment environment 2
3 Not Topics Technology and Tech. Platforms Regulatory IP User Consolidation IT/i-Phone/Cellphones 3
4 Topics Major trends and drivers Consolidation of Suppliers Platforms/Modularity Growth Driver; POC Growth Driver; Molecular Diagnostics Growth Driver; Companion Diagnostics 4
5 Big is beautiful Company Market share (%) Clear dominance of the leading 15 companies, which account for almost 90 % of the global IVD market 8 companies = 80% Roche Diagnostics 22 Abbott Diagnostics 12.6 Ortho/LifeScan 11.1 Bayer /Siemens 9.2 Beckman Coulter 6.4 Dade Behring /Siemens 5.8 BD 6.2 biomerieux 3.8 Bio-Rad 2.1 Others
6 Consolidation drives for scale, segment presence and profitability Abbott Medisense, Murex, Sequoia Turner Siemens DPC, Dade Behring, Bayer Ortho Dade Behring; Baxter, Behring, Syva Bayer; Ames, Technicon, Corning Kodak, Micro Typing Systems, DuPont 6
7 Consolidation Is Not Over 2009/10 Beckman-Coulter Olympus Life Science IVD Business $800 million acquisition $500 million additionnel sales $50-60 bottom line + Another $50 million «synergies» New customer IA base Broader CC customer base 7
8 Topics Major trends and drivers Consolidation of Suppliers Platforms/Modularity Growth Driver; POC Growth Driver; Molecular Diagnostics Growth Driver; Companion Diagnostics 8
9 Topics Major trends and drivers Consolidation of Suppliers Platforms/Modularity Growth Driver; POC Growth Driver; Molecular Diagnostics Growth Driver; Companion Diagnostics 9
10 POC Industry Snapshot Estimate Point of Care (POC) to be roughly $3B, excluding non-ivd applications and Whole Blood Glucose testing What is it? Patient self test (PST), physician office lab (POL), and hospital based POC Overall IVD market growth is at 6%-7% annually POC category growth better, at 10%-12% Hospital Labs 48% Commercial Labs 29% Self Testing 16% POC 7% IVD Market R. Sutherland Feb
11 Clinical use of in vitro diagnostic products in point of care settings* Risk screening Hs-CRP, Hcy Diagnosis CRP, HbA1c, ACR, Ferritin/Hb, TSH, pro-bnp, TnT/I, Mb, CK- MB, D-dimer, HAI s**, Flu Disease / treatment monitoring INR PT, HbA1c, ACR, CRP, Ferritin/Hb, TSH/TT4, HAI s, urine albumin Relapse INR PT, HbA1c, ACR, CRP, Ferritin/Hb, pro-bnp, TnT/I, Mb, CK- MB, D-dimer, HAI s *Excludes OTC and home testing ** Hospital/Healthcare Acquired/Associated Infections 11
12 Whole gamut of instruments and technologies No dominant over-reaching standard = many niches = many opportunities 12
13 POC; what has Wall Street s attention? Infectious disease Rapid testing ( HIV coming?) PST: New and more accurate meters (WBG and Coagulation) Rapid hospital acquired infection (HAI) testing seen as potentially explosive in hospital POC and POL POCCompanion Diagnostics? Warfarin metabolism testing could be the poster child. FDA is clearly supportive. POC BNP Rapid Testing Rapid HIV POC MRSA Market Perspectives on the POC Diagnostics Industry MassMEDIC; September 12,
14 PST Coagulation Coagulation monitoring is a sizeable market. 3MM patients on some form of anti-coagulation therapy in the US alone - 34MM tests annually. WW sales of coagulation testing equipment and reagents exceed $1B annually. PST component of this market is 8-10% today, and could grow to 20% by Additional indications (especially A Fib) could be the driver, with data available in Addressable patients Mechanical heart valve 969,000 1,028,311 Atrial fibrilation 4,781,700 5,301,556 DVT 1,786,400 1,868,000 Other CV 501, ,409 Prophylaxis and post surgery 1,537,500 1,779,848 Total tested patients 7,290,840 8,609,080 Total patient opportunity 9,576,200 10,550,124 Coagulation Meter 14
15 (POC) MRSA MRSA infections are ubiquitous, dangerous, and costly. The incidence of MRSA (Methicillin Resistant Staph Aureus) infections is rising in both hospitals and long term care facilities. In the ICU, infection rates approach 60% with 90K patients dying annually as a result of hospital-acquired infections, including those caused by MRSA. Both POL and hospital STAT applications MRSA screening is the single most important new market for molecular diagnostics. Currently valued at $1.2 billion in the US, potential $2.2 billion if screening technologies can be applied in smaller hospitals, out-patients facilities and long-term care facilities. Estimated 2008 US Inpatient Volume ICU Admissions, 4,873,755 Non-critical Admissions, 38,641,912 15
16 FDA News FOR IMMEDIATE RELEASE January 2, 2008 FDA Clears First Quick Test For Drug-Resistant Staph Infections Test Identifies MRSA Bacterium in Two Hours Remarkable annual cost savings have been demonstrated in hospitals implementing active MRSA surveillance programs. BD GeneOhm MRSA Assay 16
17 POC Challenges POC formats still tend to cost more than central lab tests Reimbursement, reimbursement, reimbursement a mixed bag. POC coagulation a poster child for challenges POL getting beyond the 30,000 or so larger POLs will smaller practices ever really want to get into the blood handling/billing business? Getting CLIA waived tests can take time, money Hospital POC: turf issues between central lab and POC advocates Technical especially in the more esoteric segments making rapid POC more accessible. Will there ever be a user friendly molecular format? 17
18 Topics Major trends and drivers Consolidation of Suppliers Platforms/Modularity Platforms/Modularity Growth Driver; POC Growth Driver; Molecular Diagnostics Growth Driver; Companion Diagnostics IVD Market R. Sutherland Feb
19 Molecular Diagnostics Unchained PCR patent expiry offers NA technology growth Patent expiry is expected to unlock considerable market opportunities End of an Era: PCR Patent; WHAT the dominance of Microsoft Windows is to personal computers, the dominance of the polymerase chain reaction is to biotechnology. The core PCR technique is now in the public domain IVD IVD Market Market R. R. Sutherland Feb JAN
20 Service Model and Product Model The molecular diagnostics industry is segmented into two major markets: service and in vitro diagnostics. different growth curves, target different niches, the service market is about 1.7 billion dollars in the U.S. globally, about 2.5 billion, the IVD market is ca $1.3 billion in the U.S. globally, about $1.9 billion. The service segment of molecular diagnostics is growing by an average of 25% pa. Infectious diseases comprise 80% growing at a rate of only 10% 15%. Eg Third party sequencing services are provided by -600 Contract Research Organizations. Today, genetics testing is responsible for driving growth of the overall molecular diagnostics market, currently constituting 7% 8% of the clinical testing service market. In the service segment, genetics testing is growing by 60% 75% per year. Recently, the Abbott -Celera alliance hit the market with products for Cystic Fibrosis & HIV drug resistance,. There are no approved products on the market for genetics; they are mostly home-brews. Oncology accounts for the remainder of the overall molecular diagnostics market. While oncology is only at 5% or less of the total market, this segment is growing at a rate of over 100%. 20
21 Totally new markets-technology Driven Jan 2010:Illumina launches the HiSeq 2000 decode a person s DNA in one week using $10,000 worth of materials five times cheaper than any other competing gadget on the market BGI (formerly the Beijing Genomics Institute) has agreed to purchase a whopping 128 of the new sequencing systems BGI s order will ultimately allow it to sequence 11,000 human genomes per year 21
22 Totally new markets-technology Driven NHGRI Plans to Award $9.5M for '$1,000 Genome' Sequencing Tech Development in FY 2010 Sequence-by-Service - Nov 2009: Complete Genomics; sequenced three whole-genomes for an average materials cost of $4,400 and reports that it is selling whole-genome sequences at $20,000 apiece in minimum orders of five, with the price dropping as the order size increases Complete Genomics publishes a genome - November 05, 2009 «Meanwhile, dozens of new sequencing companies are working away in garages and office parks on ever-better technologies that will further cut costs and timelines. Personal genomics has been a long time coming, but if these companies can deliver, we shouldn't have to wait too much longer. 22
23 Many opportunities in ID outside HIV and HCV QIAGEN to Supply Singapore Ministry of Health With Avian Flu Surveillance Solutions (Jan. 8, 2008) Awarded an exclusive contract by the Singapore Ministry of Health to supply sample preparation solutions and molecular tests for the specific detection of Influenza H5N1 viruses. The contract with the Singapore Ministry of Health is the latest supply agreement of QIAGEN with public and private institutions engaged in H5N1 surveillance. More than 80 institutes worldwide involved in the surveillance of avian flu infection use procedures and reagents developed and offered by QIAGEN 23
24 Qiagen first mover in Molecular IVD Consolidation May 2005; acquired the PCR diagnostics company Artus paid approximately $39.2 million diagnostic systems for use in the detection of infectious diseases such as SARS, Herpes simplex virus -1/-2, EBV, West Nile Virus, Malaria, Salmonella. June, 2007, acquired Digene for $1.6 billion only FDA approved manufacturer of a molecular diagnostic test for human papilloma virus (HPV), November 2009, QIAGEN to acquire SABiosciences a privately-held developer and manufacturer of disease- and pathway-focused PCR assay panels > 100 real-time PCR assay panels analysis of DNA, RNA, epigenetic and microrna targets associated with cancer and apoptosis 24
25 Qiagen first mover in Molecular IVD Consolidation Sep 2009, acquisition of UK company DxS up to $130M DxS has established over a dozen partnerships with leading pharmaceutical companies to develop companion diagnostic tests for a variety of disease states. working with Bristol-Myers Squibb and Eli Lilly subsidiary ImClone Systems to develop a companion diagnostic for Erbitux. In July, the company announced an agreement with AstraZeneca to develop a companion diagnostic for Iressa. real-time PCR tests, including a test for the mutation status of the oncogene KRAS, which is indicative for successful treatment of patients with metastatic colorectal cancer using EGFR inhibitors. TheraScreen: K-RAS Mutation Kit, is CE-marked. Expects to contribute approximately $6 million sales 2009 and approximately $30 million in sales in
26 Topics Major trends and drivers Consolidation of Suppliers Platforms/Modularity Growth Driver; POC Growth Driver; Molecular Diagnostics Growth Driver; Companion Diagnostics IVD Market R. Sutherland Feb
27 Will Companion Diagnostics finally be «Personalised medecine» February, 2009 Novartis Launches Molecular Dx Unit to Get Jump on Companion Diagnostics in-house molecular diagnostics unit in order to improve the co-development of companion diagnostics and drugs oncology is "obviously a very opportune place" for the drugmaker to begin developing companion diagnostics estimates Novartis s early molecular diagnostics portfolio will be about 50% oncology related. 27
28 Will Companion Diagnostics finally be «Personalised medecine» Diagnostics kits will be developed on the same timeline as medicines, so that the drugs and their companion diagnostics can reach the market simultaneously in-house strategy the areas that can benefit most from a drugdiagnostics combination are oncology and infectiousdisease management companion diagnostics may threaten the blockbusterdrug model because they limit the number of candidates for a drug But Its inevitable potential benefits for the patients could be fantastic 28
29 Companion Diagnostics already exist? Warfarin metabolism testing could be first salvo FDA has signaled their support Current turnaround time is generally described as not quick enough Rapid, easy to use testing formats are coming to market 29
30 Companion Diagnostics; its started already January 24, 2008 AutoGenomics Gets FDA OK for Warfarin MDx Assay US Food and Drug Administration clearance to market its Infiniti 2C9-VKORC1 Multiplex Assay for warfarin sensitivity In August 2007, FDA updated labelling for warfarin with information explaining that people with variations of the genes CYP2C9 and VKORC1 may respond differently to the drug 30
31 Topics Overall market size and segmentation Major trends and drivers Consolidation of Suppliers Platforms/Modularity Growth Driver 1; POC Growth Driver 2; Molecular Diagnostics Growth Driver 3; Companion Diagnostics Investor attitudes IVD Market R. Sutherland Feb
32 Wall Street s Take IVDs historically not seen as glamorous as other medical device categories- less IP, less R&D IVD growth rates were lower than other Med Tech categories Consolidation in the central lab meant less pricing leverage for IVD vendors IVD companies were often viewed as cash cows without the capital needs that typically attract Wall Street attention 32
33 A New Point of View? Sector now being viewed much differently IVD companies are uber defensive plays - in turbulent markets providing even greater cash flow and earnings visibility than their more volatile Device/Biotech counterparts The Razor/Razor Blade business model provides the same demographic attractiveness as other health care groups, but with far lower volatility Perception: IVD companies have far less exposure to reimbursement risk. Recent game changers have made the IVD sector more visible: High growth single markers i.e. BNP and MRSA Molecular diagnostics heading to POC and no PCR royalties Companion Diagnostics now seem to be real Lastly M&A. There is nothing more attention-getting than a lot of acquisition activity in a sector. IVD Market R. Sutherland Feb
34 Some General Conclusions Small companies will lead on innovation & establish market presence through differentiated technology. POC is here to stay PCR is unchained Small is still good Totally new markets and significant growth from Asia-PAC $40 billion in 2010? 34
Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities
Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities Introduction The report analyzes current and potential world molecular diagnostics markets and advances in the field.
More informationWhat it takes to make a new state of the art diagnostics platform for Point of Care use.
What it takes to make a new state of the art diagnostics platform for Point of Care use. 31.10.2006 Axis-Shield plc 450 employees Turnover 58 million Profit before tax 1,9 million R&D spend 7,4 million
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationFrom Resilience To Growth:
From Resilience To Growth: Mapping a New Direction for Life Sciences & Medical Devices Attorney Advertising Prior results do not guarantee a similar outcome Models used are not Mapping the Way: Opportunities
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More information35th Annual J.P. Morgan Healthcare Conference
35th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January, 2017 Safe Harbor Statement Certain statements made during the course
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationWebinar July 9, Noon. The Essentials of Diagnostics: Introduction to Molecular Diagnostics
Webinar July 9, 2013 12 Noon The Essentials of Diagnostics: Introduction to Molecular Diagnostics 1 DxInsights mission is to educate healthcare stakeholders on the power and value of diagnostics and their
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationMolecular Diagnostics for Global Heath Problems. Proactive Investors Forum 5 October 2017
Molecular Diagnostics for Global Heath Problems Proactive Investors Forum 5 October 2017 2 Document Information The information contained in this document and made verbally to you (together the Presentation
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationBiocartis: pushing boundaries in healthcare. Hilde Windels Dag van de Tips 10 October 2015
Biocartis: pushing boundaries in healthcare Hilde Windels Dag van de Tips 10 October 2015 2 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company").
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationGlobal In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
More informationMr. Lou Panaccio Executive Chairman
Mr. Lou Panaccio Executive Chairman 1 Overview Objective Develop compelling multiplexed test solutions for the $4BN global molecular diagnostic testing industry using our silica bead based AmpaSand technology
More informationClassification under the IVD Regulation
Classification under the IVD Regulation Nick Baker Head of IVD Notified Body LRQA Ltd Improving performance, reducing risk IVD regulation shift in regulatory scrutiny Under the current IVD directive 10-15%
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationMolecular Diagnostics
Molecular Diagnostics Positioning the Laboratory for the Future Through Scalable Lab Developed Test Workflows, Clinical-level Quality, & Operational Efficiency Path to the heart of healthcare Change It
More informationFirms and Federal Labs Flock to Seek FDA Emergency Use Authorization for Ebola MDx Assays
Firms and Federal Labs Flock to Seek FDA Emergency Use Authorization for Ebola MDx Assays October 21, 2014 Firms and Federal Labs Flock to Seek FDA Emergency Use Authorization for Ebola MDx Assays By Madeleine
More informationInvestors presentation results and operational advances
Investors presentation 2016 results and operational advances Disclaimer The presentation and the information it contains do not constitute an offer to sell or subscribe for on the solicitation of an offer
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. India In-Vitro Diagnostics Market Introduction Market Overview Growth Drivers Constraints Regulatory Framework and Accreditation 2. India In-Vitro Diagnostics Market Size by Revenues,
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationDiagnostics for Utopia. Company Introduction
Diagnostics for Utopia Company Introduction Contents SUMMARY Ⅰ. Current Status of the Company Ⅱ. IVD Market Trends & Future Forecast Ⅲ. Market Analysis and Marketing Strategy Ⅳ. Company Location 1 SUMMARY
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationStrategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002
Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002 Gill Butler has worked in the pharmaceutical industry for 21 years,
More informationExamples of founding and evolving leading LifeScience companies. November 2016
Examples of founding and evolving leading LifeScience companies November 2016 Peter Pohl Born: in Salzburg Love: my wife and my two children (age 9&7) Education: Business Adminstration Serial entrepreneur
More informationKonica Minolta to Acquire Ambry Genetics (US)
Konica Minolta to Acquire Ambry Genetics (US) Full-fledged Entry into Precision Medicine July 6, 2017 0 1. Transaction Details and Positioning in KM s Strategy 2. Full-fledged Entry into Precision Medicine
More informationSeegene 2017 Investor Relations
Seegene 2017 Investor Relations 2017. 4 Seegene Overview Overview of Seegene CEO/CTO: Dr. Jong-Yoon Chun Established: Sept. 15, 2000 Listed on KOSDAQ: Sept. 10, 2010 Paid-in capital: KRW 13,117mn (as of
More informationNeue Technologien für die patientennahe personalisierte Diagnostik
Neue Technologien für die patientennahe personalisierte Diagnostik 2014 Dr. Soeren Schumacher, M.B.A. 27th of June 2014 1 A heterogeneous pool 27th of June 2014 2 A heterogeneous pool Personalized Medicine
More informationPOC Lipid Testing Market: US, Germany, Spain Physician Offices, Emergency Rooms, Ambulatory Care Centers. Table of Contents
POC Lipid Testing Market: US, Germany, Spain Physician Offices, Emergency Rooms, Ambulatory Care Centers Introduction Executive Summary Table of Contents Rationale for Testing Decentralization 1. Overview
More informationQuantStudio Dx Real-Time PCR Instrument
QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help
More informationInvestor Presentation
Investor Presentation 2017 www.enzo.com LEGAL DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward looking" statements within the meaning of Section 27A
More informationSingle Cell Genomics (SCG): Market Size, Segmentation, Growth, Competition and Trends ( )
Single Cell Genomics (SCG): Market Size, Segmentation, Growth, Competition and Trends (2013-2021) May, 2017 3 rd Edition Information contained in this market report is believed to be reliable at the time
More informationFor personal use only
ASX ANNOUNCEMENT Non-Deal Roadshow Presentation 25 May 2015 Sydney, 25 May 2015: Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that John Melki, PhD., Director & CEO and
More informationMOLECULAR DIAGNOSTICS TESTING: Industry Overview and SCM Challenges
MOLECULAR DIAGNOSTICS TESTING: Industry Overview and SCM Challenges Alan Wells, Vice President, Diagnostics Laboratory Operations, Life Technologies Mike Crowell, Sr. Director of Supply Chain, Verinata
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationAn Economic Analysis of Generic Drug Usage in the U.S.
September 2011 $931 Billion SAVINGS An Economic Analysis of Generic Drug Usage in the U.S. EXECUTIVE SUMMARY As government leaders in Washington and across the country look for ways to cut health care
More informationAs Yogi Berra famously said, When
Delivering Cancer Diagnostics Tools With regulatory changes anticipated but not yet articulated, it s hard to know the best path forward for companies developing cancer diagnostics-related tools and tests.
More informationGENERAL PAYER CONSIDERATIONS FOR NEW HEALTH TECHNOLOGIES (INCLUDING DIAGNOSTICS)
FORUM Payer perspectives and actions impacting diagnostics in the US and Europe Eric Faulkner, MPH Director, Quintiles Global Market Access Consulting; Executive Director, Genomics Biotech Emerging Medical
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 4 Stephanie A. Hamilton, EdD, SCT, MB(ASCP) CM MD Anderson
More informationAmoyDx JAK2 Mutation Detection Kit
AmoyDx JAK2 Mutation Detection Kit Detection of V617F mutation in the JAK2 oncogene Instructions For Use For Research Use Only and For Reference Only Instructions Version: B1.2 Date of Revision: June 2016
More informationNext Generation Sequencing (NGS) Market Size, Growth and Trends ( )
Next Generation Sequencing (NGS) Market Size, Growth and Trends (2014-2020) July, 2017 4 th edition Information contained in this market report is believed to be reliable at the time of publication. DeciBio
More informationAligning Lab Goals & Institutional Goals Laughlin Rice
Aligning Lab Goals & Institutional Goals Laughlin Rice Senior Administrative Director Department of Pathology & Laboratory Medicine The Children s Hospital of Learning Objectives To understand the institutional
More informationRenub Research Global Molecular Diagnostics Market & Future Forecast
Renub Research www.renub.com Global Molecular Diagnostics Market & Future Forecast 2010 2014 Publisher: Renub Research Published: July, 2011 Global Molecular Diagnostics - Market Overview The global molecular
More informationMOLECULAR DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS
MOLECULAR DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS BIO063C June 2015 Jon Evans Project Analyst ISBN: 1-62296-110-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationInnovations in Molecular Lab Operation. Joseph M. Campos, PhD, D(ABMM), F(AAM)
Innovations in Molecular Lab Operation Lessons in the Best Ways to Blend Automation, Lean Workflow, and Paperless Processes Joseph M. Campos, PhD, D(ABMM), F(AAM) Interim Chief, Division of Laboratory
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationMEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS HLC170B January 2017 Vijay Laxmi Project Analyst ISBN: 1-62296-410-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationHistory has Demonstrated that Sub-optimal CDx Strategies can Impact Drug Success
DOES YOUR COMPANION DIAGNOSTIC STRATEGY BEST P OSITION YOU FOR SUCCESS? History has Demonstrated that Sub-optimal CDx Strategies can Impact Drug Success Real-World Examples 1 st Year Sales Increased complexity
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationThe China In Vitro Diagnostics (IVD) Market has been analyzed from 4 View Points:
China In Vitro Diagnostics (IVD) Market - Overview China In-Vitro Diagnostics (IVD) market is among the fastest growing in the world. It is anticipated that China IVD market will more than triple by 2020
More informationPhilips: a focused leader in HealthTech
Philips: a focused leader in HealthTech Frans van Houten, CEO Royal Philips 36th Annual J.P. Morgan Healthcare Conference, San Francisco, USA January 9, 2018 Important information Forward looking statements
More informationUpdate on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations
Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations Paul Brooks Vice President Healthcare, Americas Presentation to:
More informationGenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING. J.P. Morgan Healthcare Conference 2018
GenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING J.P. Morgan Healthcare Conference 2018 1 Forward-Looking Statements This presentation contains forward-looking statements about GenMark Diagnostics,
More informationEpstein Barr Virus (Human Herpes virus 4)
TM Primerdesign Ltd Epstein Barr Virus (Human Herpes virus 4) nonglycosylated membrane protein (BNRF1) gene genesig Standard Kit 150 tests For general laboratory and research use only 1 Introduction to
More informationAIT Austrian Institute of Technology
AIT Austrian Institute of Technology Expert view of Biomedical Engineering and Care Services Brussels,, 09:30 a.m. to 13:00 p.m. EESC, Jacques Delors Building, Room JDE 61, rue Belliard 99 Manfred Bammer,
More informationForecast diagnostics for antimicrobial resistance (AMR)
Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford Context When asked to make forecasts
More informationInnovating out of Crisis
Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationGENETIC TESTING A Resource from the American College of Preventive Medicine
GENETIC TESTING A Resource from the American College of Preventive Medicine A Time Tool for Clinicians ACPM's Time Tools provide an executive summary of the most up-to-date information on delivering preventive
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationStrategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical
Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings
More informationIntegrating Genomics in Family Medicine
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationUBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More informationInstrument specifications Technology Software Host interfaces Printer interfaces Data Station Physical dimensions Weight Certifications
The evolution of PCR Introducing the COBAS TaqMan 48 Analyzer At the forefront of PCR evolution Since Roche acquired the rights to PCR in 1991, its mission has been to fully realize the potential of this
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationValidation and Verification Of Molecular Diagnostic Tests Gregory J. Tsongalis, Ph.D.
Validation and Verification Of Molecular Diagnostic Tests Gregory J. Tsongalis, Ph.D. Professor of Pathology Director, Molecular Pathology Dartmouth Medical School Dartmouth Hitchcock Medical Center Norris
More informationCHARTING THE COURSE FOR PRECISION MEDICINE
A Friends of Cancer Research White Paper CHARTING THE COURSE FOR PRECISION MEDICINE ADOPTING CONSENSUS ANALYTICAL STANDARDS AND STREAMLINING APPROVAL PATHWAYS FOR POST-MARKET MODIFICATIONS FOR NGS TESTS
More informationWorld Congress on Industrial Biotechnology May, 2014
World Congress on Industrial Biotechnology May, 2014 1 The Value Proposition Leader in precision gene editing RTDS Non transgenic, non GMO platform RTDS Broadly applicable across many organisms Significant
More informationUpdate on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
More informationBIOANALYTICAL AND BIOMEDICAL MICROSENSORS. Gerald A. URBAN Laboratory for Sensors IMTEK Freiburg/Germany. G. A. Urban Slide 1 3
BIOANALYTICAL AND BIOMEDICAL MICROSENSORS Gerald A. URBAN Laboratory for Sensors IMTEK Freiburg/Germany G. A. Urban Slide 1 3 DISTINGUISHING FEATURES Unique combination of Computer Science and Microsystems
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationAdam Schechter President, Global Human Health. Merck & Co., Inc. Cowen 2015 Healthcare Conference. March 3, 2015
Adam Schechter President, Global Human Health Merck & Co., Inc. Cowen 2015 Healthcare Conference March 3, 2015 Forward-Looking Statement This communication includes forward-looking statements within the
More informationThe future of PMS in Healthcare IT: Announcing the cooperation with Epic. Stan Smits CEO Medical IT Philips Medical Systems
The future of PMS in Healthcare IT: Announcing the cooperation with Epic Stan Smits CEO Medical IT Philips Agenda Healthcare IT: business rationale Why Epic? Scope of the cooperation agreement Company
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationFor personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationIQ4I Research. and Consultancy. Research and Consultancy v4023/ Publisher Sample
IQ4I Research and Consultancy http://www.marketresearch.com/iq4i Research and Consultancy v4023/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday -
More informationGENOMICS WORLD MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications May 2008 Volume: TMRGEN08-0515 GENOMICS WORLD MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS 1. Introduction
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.
More informationAmoyDx JAK2 Mutation Detection Kit
AmoyDx JAK2 Mutation Detection Kit Detection of V617F mutation in the JAK2 oncogene Instruction for Use For Research Use Only Instruction Version: B2.6 Revision Date: October 2013 Store at -20±5 Xiamen,
More informationPositioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory. Giorgio Roscigno CEO FIND
Positioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory Giorgio Roscigno CEO FIND Integrated Laboratory Network Definition An integrated laboratory
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More information2017 European Molecular Diagnostics for Infectious Disease New Product Innovation Award
2017 European Molecular Diagnostics for Infectious Disease New Product Innovation Award Contents Background and Company Performance... 3 Industry Challenges... 3 New Product Attributes and Customer Impact...
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationnot to be republished NCERT BIOTECHNOLOGY AND ITS APPLICATIONS CHAPTER BIOLOGY, EXEMPLAR PROBLEMS MULTIPLE-CHOICE QUESTIONS
82 BIOLOGY, EXEMPLAR PROBLEMS CHAPTER 12 BIOTECHNOLOGY AND ITS APPLICATIONS 1. Bt cotton is not: a. A GM plant b. Insect resistant MULTIPLE-CHOICE QUESTIONS c. A bacterial gene expressing system d. Resistant
More informationChoose only what you really need
The LightMix Modular Assays Choose only what you really need PICK CREATE RUN The LightMix Modular Assays ONE simple concept, THREE big benefits Easy to Use Select from a huge range of ready-to-use individual
More informationAmoyDx TM JAK2 V617F Mutation Detection Kit
AmoyDx TM JAK2 V617F Mutation Detection Kit Detection of V617F mutation in the JAK2 oncogene Instructions For Use Instructions Version: B1.0 Date of Revision: July 2012 Store at -20±2 o C -1/5- Background
More informationOutline of the Business Alliance
Notification with Respect to the Basic Agreement Between FUJIFILM Holdings Corporation, Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd. Regarding a Strategic Capital and Business Alliance
More informationThis Webcast Will Begin Shortly
This Webcast Will Begin Shortly If you have any technical problems with the Webcast or the streaming audio, please contact us via email at: webcast@acc.com Thank You! Personalized Medicine Promise and
More information